Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best pharma stocks to invest in. On December 4, Jefferies reiterated a Buy rating on Bristol-Myers Squibb Company (NYSE:BMY) with a price target of $68.

The same day, Scotiabank lifted the price target on Bristol-Myers Squibb Company (NYSE:BMY) to $53 from $45 while maintaining a Sector Perform rating on the shares. The firm told investors that it anticipates several pivotal and registrational data readouts in 2026, adding that these readouts have a risk/reward to the upside.

The two rating updates came the same day Bristol-Myers Squibb Company (NYSE:BMY) announced that the U.S. Food and Drug Administration (FDA) granted approval for Breyanzi to treat adult patients living with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy. Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T cell therapy and is administered as a one-time infusion.

The approval makes it the only FDA-approved CAR T cell therapy for five cancer types, which is the most of any CD19-directed CAR T cell therapy. Breyanzi exhibited durable and deep responses in 95.5% of patients in the MZL cohort of TRANSCEND FL, while demonstrating a consistent safety profile.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.